Who is sponsoring NCT01833208?

NCT01833208 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT01833208?

Interventions in NCT01833208: Laboratory Biomarker Analysis, Radiation Therapy.

What condition does NCT01833208 study?

NCT01833208 studies Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer.

Is NCT01833208 still recruiting?

NCT01833208 is currently completed. Last updated 5 August 2021.

Last reviewed 2021-08-05 · How we verify

NCT01833208

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Completed NA Last updated 5 August 2021

What this trial tests

NA trial testing Laboratory Biomarker Analysis in Hormone-Resistant Prostate Cancer in 15 participants. Completed in 23 January 2021.

Timeline

3 July 2013

Primary endpoint
6 August 2018

23 January 2021

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	3 July 2013
Primary completion	6 August 2018
Estimated completion	23 January 2021
Sites	2 locations across United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Radiation Therapy — full drug profile →

Conditions studied

Hormone-Resistant Prostate Cancer — all drugs for Hormone-Resistant Prostate Cancer →
Metastatic Malignant Neoplasm in the Bone — all drugs for Metastatic Malignant Neoplasm in the Bone →
Recurrent Prostate Carcinoma — all drugs for Recurrent Prostate Carcinoma →
Stage IV Prostate Cancer — all drugs for Stage IV Prostate Cancer →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, male only, with Hormone-Resistant Prostate Cancer or Metastatic Malignant Neoplasm in the Bone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot clinical trial studies the impact of radiation therapy on the immunogenicity of Sipuleucel-T. Patients with castration recurrent prostate cancer who are eligible for treatment with Sipuleucel-T and who have bone metastases are eligible.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current clinical trials testing the combination of immunotherapy with radiotherapy.
Kang J, Demaria S, Formenti S. · · 2016 · cited 293× · PMID 27660705 · DOI 10.1186/s40425-016-0156-7
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
Saxena M, Bhardwaj N. · · 2018 · cited 231× · PMID 29458962 · DOI 10.1016/j.trecan.2017.12.007
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE, Antonarakis ES. · · 2018 · cited 124× · PMID 29260582 · DOI 10.2217/fon-2017-0531
Trial watch: Dendritic cell-based interventions for cancer therapy.
Vacchelli E, Vitale I, Eggermont A, Fridman WH, et al · · 2013 · cited 91× · PMID 24286020 · DOI 10.4161/onci.25771
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.
Gdowski AS, Ranjan A, Vishwanatha JK. · · 2017 · cited 83× · PMID 28800754 · DOI 10.1186/s13046-017-0578-1
Trial watch: Dendritic cell-based anticancer therapy.
Bloy N, Pol J, Aranda F, Eggermont A, et al · · 2014 · cited 56× · PMID 25941593 · DOI 10.4161/21624011.2014.963424
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
Madan RA, Antonarakis ES, Drake CG, Fong L, et al · · 2020 · cited 54× · PMID 32145020 · DOI 10.1093/jnci/djaa021
Radiation therapy and immunotherapy: what is the optimal timing or sequencing?
Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, et al · · 2018 · cited 51× · PMID 29421979 · DOI 10.2217/imt-2017-0082

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other recruiting trials for Hormone-Resistant Prostate Cancer

Currently open trials in the same condition.

NCT02881242 — Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer · Phase 2 · active not recruiting
NCT02312557 — Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzaluta · Phase 2 · active not recruiting
NCT01953640 — Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy · active not recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01833208 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 5 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01833208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing